Archives

Gratifii Limited (GTI) has announced a change in director Michael Hill's shareholding following a shareholder-approved placement conducted in July 2026. Hill acquired 625,000 fully paid ordinary shares at $0.04 per share and received 312,500 free attaching unlisted options as part of the capital raise. The transaction was approved by shareholders at an Extraordinary General Meeting on 13 July 2026 and completed on 21 July 2026.

• July 21, 2026 04:10 PM AEST
• Aditi Sarkar

Gratifii Limited (GTI) has disclosed a change in director holdings following a shareholder-approved capital raise. Director Patrina Kerr acquired 625,000 fully paid ordinary shares and 312,500 unlisted options through a placement on 21 July 2026, investing $25,000 at $0.04 per share. The transaction was approved by shareholders at an Extraordinary General Meeting on 13 July 2026 and executed during a closed period with prior ASX clearance. The acquisition increases Kerr's direct shareholding to 3.48 million shares, reflecting continued director confidence in the company.

• July 21, 2026 04:10 PM AEST
• Manish Choudhary

Gratifii Limited (GTI) has disclosed a change in director shareholdings following a placement approved by shareholders. Director Iain Dunstan acquired 625,000 fully paid ordinary shares at $0.04 per share, together with 312,500 free attaching unlisted options, on 21 July 2026. The transaction was conducted under a shareholder-approved placement and included prior written clearance during the company's closed period.

• July 21, 2026 04:10 PM AEST
• Manish Choudhary

The sleep and breathing-health specialist agreed to divest a non-core software arm, streamlining itself around its highest-growth ambitions. The move landed as healthcare names clawed back ground from steep lows, giving the cleaner strategy extra room to be rewarded. Tickers used:ASX:RMD Alternate headline 1:Can ResMed's sharper focus revive its growth story? Alternate headline 2:ResMed offloads software arm to chase core growth

• July 21, 2026 04:10 PM AEST
• Sam

The hearing-implant leader stunned the market by slashing its profit outlook for the year, citing softer demand and shipment disruption tied to conflict overseas. The downgrade rippled across a healthcare sector whose mood was already fragile after a difficult stretch. Tickers used:ASX:COH, ASX:PME Alternate headline 1:Why did Cochlear's downgrade rattle ASX healthcare? Alternate headline 2:Cochlear guidance cut jolts ASX healthcare mood

• July 21, 2026 04:10 PM AEST
• Sam

Explore how leading gold mining companies are responding to new project milestones, regulatory developments and operational priorities as the global gold sector continues to evolve.

• July 21, 2026 04:07 PM AEST
• Sam

CSL shares steadied as the ASX healthcare sector rebounded sharply from a multi-year low. A bruising year of downgrades and writedowns had left the blood-products major deeply out of favour before the bounce.

• July 21, 2026 04:06 PM AEST
• Sam

Cochlear stunned the market by slashing its profit outlook, citing softer demand and shipment disruption. The downgrade rippled across an ASX healthcare sector still nursing a fragile mood after a difficult year.

• July 21, 2026 04:06 PM AEST
• Sam

ResMed agreed to divest a non-core software business to sharpen its focus on sleep and breathing health. The move, part of a longer-term growth plan, landed as ASX healthcare names clawed back ground from steep lows.

• July 21, 2026 04:06 PM AEST
• Sam

Explore why Genmin is attracting growing attention as insider ownership rises, what it signals about the company's long-term strategy, and the broader factors influencing its future development plans.

• July 21, 2026 04:04 PM AEST
• Sam